Back to top
more

Protagonist Therapeutics (PTGX)

(Delayed Data from NSDQ)

$53.90 USD

53.90
438,148

+0.07 (0.13%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $53.89 -0.01 (-0.02%) 6:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -4.48% and 199.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for October 14th

by Zacks Equity Research

ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Moves 18.2% Higher: Will This Strength Last?

by Zacks Equity Research

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -11.29% and -59.55%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Protagonist Therapeutics (PTGX) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Stock Jumps 9.3%: Will It Continue to Soar?

by Zacks Equity Research

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Company News for Jun 14, 2021

by Zacks Equity Research

Companies In The News Are: VRTX, RCL, AAL, PTGX

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.26% and 65.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Protagonist Therapeutics (PTGX) Soars 5.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -2.13% and 67.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

MannKind (MNKD) Looks Good: Stock Adds 5.6% in Session

by Zacks Equity Research

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235

by Zacks Equity Research

Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 65.57% and 245.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Protagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag

by Zacks Equity Research

The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.

Zacks Equity Research

Company News for May 11, 2020

by Zacks Equity Research

Companies In The News Are: FTEK, PTGX, SXC, ZG

Madeleine Johnson headshot

Why Did Protagonist Therapeutics (PTGX) Soar 83.7% Today?

by Madeleine Johnson

Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 1.56% and -48.21%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder

by Zacks Equity Research

Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 18.67% and -27.98%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?